Table 2.
Characteristics of 11 trials included in the meta-analysis.
| References | Country | Study design | Sample size | Donor type | Donor age | Recipient age | Recipient MELD scores | Perfusion device | Length of HOPE hours | CIT hours | WIT minutes | Outcomes | NOS |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dutkowski16 | Switzerland | Matched, PCS | H: 25 S: 50 |
DCD | H: 54 (36–63) S: 48 (33–51) |
H: 60 (57–64) S: 56 (49–59) |
H: 13 (9–15) S: 16 (10–21) |
ECOPS device (Organ Assist) | 2.0 (1.7–2.5) | H: 3.1 (2.4–4.4) S: 6.6 (5.8–7.5) |
H: 36 (31–40) S: 33 (27–40) |
Hospital stay, ICU stay, NAS, PNF, HAT, EAD, Acute rejection, Total biliary complication, 1-year graft survival, Retransplantation, Renal replacement therapy | 7/9 |
| van Rijn17 | The Netherlands | Matched, PCS | H: 10 S: 20 |
DCD | H: 53 (47–57) S: 53 (47–58) |
H: 57 (54–62) S: 52 (42–60) |
H: 16 (15–22) S: 20 (13–24) |
Liver Assist device (Organ Assist, Groningen, The Netherlands) | 2.1 (2.1–2.3) | H: 6.0 (5.2–6.6) S: 7.1 (6.7–8.1) |
H: 26 (23–42) S: 33 (29–41) |
Hospital stay, ICU stay, PNF, NAS, HAT, EAD, Total biliary complication, 1-year graft survival, 1-year patient survival, Retransplantation, Renal replacement therapy | 9/9 |
| Schlegel18 | Switzerland | Matched, RCS | H: 50 S: 50 |
DCD | H: 57 (47–67) S: 53 (33–60) |
H: 58 (56–62) S: 57 (51–61) |
H: 11 (8–14) S: 11.8 (8.5–15.8) |
Liver Assist device (Organ Assist) | 2 (1.6–2.4) | H: 4.4 (3.5–5.2) S:4.7 (4.3–5.3) |
H: 36 (31–40) S: 25.5 (21–31) |
PNF, NAS, Total biliary complication, Acute rejection, Renal replacement therapy | 7/9 |
| Patrono19 | Italy | RCS, PSM | H: 25 S: 50 |
DBD | H: 74.3 (10.9) S: 74.9 (10.3) |
H: 56.3 (9) S: 55.9 (7.4) |
H: 15.3 (8.6) S: 15.5 (8.5) |
Liver Assist device (Organ Assist, Groningen, The Netherlands) | 3.1 (0.8) | H: 5.2 (0.9) S:6.5 (1.2) |
H: 24 (5) S: 23 (7) |
Hospital stay, ICU stay, Acute rejection, NAS, EAD, PNF, Total biliary complication, Renal replacement therapy, Major complications | 8/9 |
| Ravaioli20 | Italy | Matched, PCS | H: 10 S: 30 |
DBD | H: 77.5 (60–84) S: 75.5 (53–85) |
H: 57.5 (50–68) S: 60.5 (48–68) |
H: 13 (7–16) S: 13.5 (7–20) |
Developed by Medica S.P.A and Centro Iperbarico S.R.L. under the scientific management of the author | 2.2 (1–3.5) | H: 7.1 (6.1–9.6) S:7 (5.4–10) |
NA | PNF, EAD, Hospital stay, Acute rejection, 1-year graft survival, 1-year patient survival, Total biliary complication, Major complications | 8/9 |
| Czigany2 | Germany | Multicenter, RCT | H: 23 S: 23 |
DBD | H: 73 (60–78) S: 71 (59–78) |
H: 60 (52–64) S: 63 (56–67) |
H: 13 (9–18) S: 17 (8–25) |
Liver Assist | 2.4 (1.7–3.4) | H: 6.3 (5.2–7.8) S:8.4 (7.8–9.7) |
H: 39 (35–54) S: 45 (39–52) |
Hospital stay, ICU stay, Acute rejection, EAD, PNF, HAT, Cost, Total biliary complication, 1-year graft survival, 1-year patient survival, Retransplantation, Major complications, Renal replacement therapy | – |
| Rayar21 | France | PCS, PSM | H: 25 S: 69 |
DBD | H: 70 (45–87) S: 72 (25–88) |
H: 63 (43–69) S: 62 (36–70) |
H: 18.3 (7–37) S: 18.3 (5–40) |
Liver Assist | 2 (1.3–4.2) | H: 8.8 (6.3–13.7) S:9.3 (3.5–12.0) |
NA | PNF, NAS, EAD, Hospital stay, ICU stay, Total biliary complication, 1-year graft survival, 1-year patient survival, Cost, Major complications, Retransplantation, Renal replacement therapy | 8/9 |
| van Rijn9 | The Netherlands | Multicenter, RCT | H: 78 S: 78 |
DCD | H: 52 (43–57) S: 49 (37–59) |
H: 60 (52–65) S: 60 (52–65) |
H: 14 (10–19) S: 16 (10–22) |
Liver Assist device (Organ Assist) | 2.2 (2.0–2.6) | H: 6.2 (5.3–6.9) S:6.8 (5.9–8.0) |
H: 29 (22–33) S: 27 (21–35) |
Hospital stay, ICU stay, EAD, PNF, Retransplantation, NAS, Total biliary complication, Major complications, Total, Post-reperfusion syndrome, HAT, Renal replacement therapy | – |
| Ravaioli22 | Italy | RCT | H: 55 S: 55 |
DBD | H: 76 (64–81) S: 72 (59–77) |
H: 57 (47–65) S: 60 (53–66) |
H: 15 (10–18) S: 14 (9–20) |
Vitasmart (Bridge to Life, DG, USA) machine | 2.4 (2-3.1) | H: 4.3 (3.6–5.4) S:7.0 (6.0–7.5) |
NA | Hospital stay, ICU stay, EAD, PNF, HAT, Retransplantation, Post-reperfusion syndrome | – |
| Grąt23 | Poland | RCT | H: 26 S: 78 |
DBD | H: 53 (40–60) S: 44 (35–56) |
H: 46 (39–62) S: 51 (41–60) |
H: 12 (8–21) S: 14 (10–21) |
Liver Assist device (Organ Assist, now XVIVO) | 2.0 | H: 7.5 (7.0–9.2) S:9.5 (8.0–10.5) |
NA | ICU stay, EAD, PNF, Major complications, Total biliary complication, Post-reperfusion syndrome | – |
| Schlegel10 | Switzerland | Multicenter, RCT | H: 85 S: 85 |
DBD | H: 59 (48–72) S: 62 (44–71) |
H: 60 (51–64) S: 57 (49–64) |
H: 20 (11–28) S: 19 (12–26) |
Liver Assist | 1.6 (1.2–2.3) | H: 6.2 (5.0–7.9) S:7.1 (5.9–8.1) |
NA | Hospital stay, ICU stay, EAD, NAS, Total biliary complication, 1-year graft survival, 1-year patient survival, Major complications, HAT | – |
CIT, cold ischemic time; DBD, donors after brain death; DCD, donors after cardiac death; EAD, early allograft dysfunction; HAT, hepatic artery thrombosis; ICU, intensive care unit; MELD, model for end-stage liver disease; NAS, non-anastomotic biliary stricture; PCS, prospective cohort study; PNF, primary non-function; PSM, propensity score matching; RCS, retrospective cohort study; RCT, randomized controlled trial; WIT, warm ischemic time.